VPS35 Retromer Pharmacological Chaperone

VPS35 Retromer Pharmacological Chaperone

Overview

This therapeutic strategy targets the retromer complex — a master regulator of endosomal protein sorting — through pharmacological chaperones that stabilize the VPS35-VPS26-VPS29 trimer. The VPS35 D620N mutation causes autosomal dominant Parkinson's disease, and retromer dysfunction is now recognized as a convergence point linking APP mis-sorting in Alzheimer's disease, GCase trafficking defects in GBA1-linked PD, and lysosomal failure across multiple proteinopathies. Small-molecule retromer stabilizers (the R33/R55 class) have demonstrated preclinical efficacy in reducing Aβ production and rescuing lysosomal function, making this one of the most mechanistically compelling multi-disease targets in neurodegeneration.[@vilariogell2011][@small2005]

Target

• Primary Target: VPS35-VPS29 interface of the retromer cargo-selective complex
• Target Type: Pharmacological chaperone / protein-protein interaction stabilizer
• Expression: Ubiquitous; critical in neurons due to extreme endosomal trafficking demand (synaptic vesicle recycling, receptor sorting)
• Localization: Endosomal membrane; cycles between early endosomes, recycling endosomes, and trans-Golgi network

Mechanistic Rationale

The retromer complex sorts cargo proteins from endosomes back to the trans-Golgi network (TGN) or plasma membrane. Its dysfunction causes catastrophic cargo mis-sorting, with downstream consequences across multiple neurodegenerative disease pathways:[@vilariogell2011]

...

VPS35 Retromer Pharmacological Chaperone

Overview

This therapeutic strategy targets the retromer complex — a master regulator of endosomal protein sorting — through pharmacological chaperones that stabilize the VPS35-VPS26-VPS29 trimer. The VPS35 D620N mutation causes autosomal dominant Parkinson's disease, and retromer dysfunction is now recognized as a convergence point linking APP mis-sorting in Alzheimer's disease, GCase trafficking defects in GBA1-linked PD, and lysosomal failure across multiple proteinopathies. Small-molecule retromer stabilizers (the R33/R55 class) have demonstrated preclinical efficacy in reducing Aβ production and rescuing lysosomal function, making this one of the most mechanistically compelling multi-disease targets in neurodegeneration.[@vilariogell2011][@small2005]

Target

• Primary Target: VPS35-VPS29 interface of the retromer cargo-selective complex
• Target Type: Pharmacological chaperone / protein-protein interaction stabilizer
• Expression: Ubiquitous; critical in neurons due to extreme endosomal trafficking demand (synaptic vesicle recycling, receptor sorting)
• Localization: Endosomal membrane; cycles between early endosomes, recycling endosomes, and trans-Golgi network

Mechanistic Rationale

The retromer complex sorts cargo proteins from endosomes back to the trans-Golgi network (TGN) or plasma membrane. Its dysfunction causes catastrophic cargo mis-sorting, with downstream consequences across multiple neurodegenerative disease pathways:[@vilariogell2011]

APP mis-sorting → increased Aβ production: Retromer normally retrieves APP from endosomes before it reaches β/γ-secretase-rich compartments. Retromer dysfunction increases APP residence time in endosomes, driving amyloidogenic processing[@muhammad2008]

GCase trafficking failure → lysosomal dysfunction: GCase (encoded by GBA1) requires retromer-dependent trafficking from TGN to lysosomes. VPS35 deficiency reduces lysosomal GCase activity, causing glucosylceramide accumulation and α-synuclein aggregation[@miura2014]

CI-MPR mis-sorting → cathepsin deficiency: Cation-independent mannose-6-phosphate receptor (CI-MPR) recycling depends on retromer; its failure starves lysosomes of cathepsins, impairing protein degradation[@seaman2012]

Wntless recycling failure → Wnt signaling defects: Retromer sorts Wntless, the Wnt ligand carrier; its loss impairs Wnt-dependent synaptic maintenance

Cross-links to relevant mechanisms:

• Retromer Complex
• VPS35 Pathway in Parkinson's Disease
• VPS35/Retromer Pathway
• Endolysosomal Trafficking Defects
• Amyloid Cascade Pathway
• Autophagy-Lysosomal Pathway

Rubric Score

| Dimension | Score | Rationale |
|-----------|-------|-----------|
| Novelty | 8/10 | Pharmacological chaperones for retromer are a first-in-class concept; R33/R55 are tool compounds, not clinical candidates yet |
| Mechanistic Rationale | 9/10 | VPS35 mutation causes monogenic PD; retromer reduction documented in sporadic AD and PD brain tissue; multiple validated cargo |
| Addresses Root Cause | 9/10 | Retromer dysfunction is upstream of Aβ production, lysosomal failure, and α-synuclein accumulation — a true convergence node |
| Delivery Feasibility | 7/10 | Small molecules; R33 class shows oral bioavailability in mice; BBB penetration demonstrated |
| Safety Plausibility | 7/10 | Stabilizing an endogenous complex rather than inhibiting/activating an enzyme; lower risk of off-target effects |
| Combinability | 8/10 | Combines with anti-amyloid (addresses different Aβ source), GCase activators (rescue lysosomal substrate), and anti-tau therapies |
| Biomarker Availability | 7/10 | CSF Aβ42/40 ratio, GCase activity assays, and retromer component levels (VPS35 in CSF exosomes) can track engagement |
| De-risking Path | 8/10 | R33/R55 tool compounds validated in APP transgenic mice; VPS35 D620N knock-in mice available; iPSC models established |
| Multi-disease Potential | 9/10 | Validated relevance in AD (Aβ), PD (VPS35, GCase), FTD (progranulin sorting), and Down syndrome (APP gene dosage) |
| Patient Impact | 8/10 | A single molecule addressing Aβ, lysosomal failure, and α-synuclein simultaneously could be transformatively disease-modifying |
| Total | 80/100 | |

De-risking Path

Phase 1 — Tool compound optimization: Improve R33/R55 scaffold for drug-like properties — optimize LogP, metabolic stability (CYP profiling), and BBB penetration (PAMPA-BBB, Pgp substrate liability)

Phase 2 — Target engagement: Demonstrate increased VPS35 protein levels, retromer assembly (co-IP), and rescued cargo sorting (APP, CI-MPR, GCase) in iPSC neurons from VPS35 D620N and GBA1 N370S carriers

Phase 3 — Multi-model efficacy: Test in APP/PS1 mice (Aβ reduction by ELISA and plaque burden), VPS35 D620N knock-in mice (DA neuron preservation, α-syn reduction), and GBA1 heterozygous mice (lysosomal GCase rescue)

Phase 4 — Combination proof-of-concept: Co-administer with ambroxol (GCase activator) to test additive/synergistic lysosomal rescue

Phase 5 — Clinical path: AD indication first (Aβ biomarker as primary PD endpoint); PD-GBA1 cohort as enriched population for lysosomal rescue signal

Disease Coverage

| Disease | Relevance | Rationale |
|---------|-----------|-----------|
| Alzheimer's Disease | High | Retromer deficiency increases amyloidogenic APP processing; VPS35 levels reduced in AD brain[@muhammad2008] |
| Parkinson's Disease | High | VPS35 D620N causes monogenic PD; retromer dysfunction impairs GCase trafficking[@vilariogell2011] |
| Frontotemporal Dementia | Medium | Progranulin (GRN) trafficking depends on sortilin-retromer interaction |
| Down Syndrome | Medium | APP triplication makes retromer-mediated APP retrieval especially critical |
| Dementia with Lewy Bodies | Medium | Overlapping synuclein pathology and lysosomal dysfunction |

Combination Therapy Potential

• With ambroxol (GCase activator): Retromer stabilizer ensures GCase reaches lysosomes; ambroxol enhances its activity once there — sequential pathway rescue
• With anti-amyloid antibodies (lecanemab/donanemab): Antibodies clear existing Aβ plaques while retromer stabilization reduces ongoing Aβ production from APP mis-sorting
• With NAD+ precursors: NAD+ supports endosomal pH maintenance and sorting fidelity through SIRT1-mediated deacetylation of VPS35

Related NeuroWiki Pages

• VPS35 Gene | VPS35 Protein
• Retromer Complex | VPS35 Pathway
• Retromer Stabilizers
• GBA1 Gene | GCase Protein
• [Endolysosomal Trafficking Defects](/mechanisms/endolysosomal-trafficking-defects)
• [Amyloid Cascade Pathway](/mechanisms/amyloid-cascade-pathway)
• APP Gene
• PSEN1 Gene | PSEN2 Gene

Actionable Next Steps

Lab Experiments

Screen retromer stabilizers: Test small molecule library in cell-based retromer assembly assay

VPS35 binding validation: Use cryo-EM to confirm binding mode of lead compounds

In vivo PK/PD: Establish brain exposure and retromer function biomarkers in mouse models

Clinical Protocol Design

Patient selection: Enrich for participants with evidence of retromer dysfunction (elevated CST3, sortilin)

Biomarker endpoints: Measure CSF biomarkers (Aβ42, p-tau, α-syn), imaging (PET)

Dose-finding: Use adaptive design to identify optimal dose

Partnership Opportunities

Denali Therapeutics: Has retromer program

Vaccinex: Has retromer-focused pipeline

Academic: Collaborate with Dr. Michael Goedert (Cambridge) or Dr. John Fink (Michigan)

Implementation Roadmap

Estimated Timeline (4-6 years to IND)

| Phase | Duration | Key Milestones |
|-------|----------|----------------|
| Lead Identification | 6-12 months | Screen retromer stabilizer library, identify brain-penetrant candidates |
| Preclinical (IND-enabling) | 18-24 months | GLP toxicology, efficacy in AD/PD models, GMP manufacturing |
| IND-enabling studies | 12-18 months | GLP toxicology, CMC, regulatory meetings |
| Phase I | 12-18 months | Safety, dose-ranging in Alzheimer's patients |

Estimated Cost

• Lead identification: $2-5M
• Preclinical development: $8-15M
• IND-enabling studies: $8-12M
• Phase I trials: $15-25M
• Total to Phase I: $33-57M

Academic Centers

University of Michigan — Dr. John Fink (retromer biology, PD)

University of Cambridge — Dr. Michael Goedert (tau, α-syn, neurodegeneration)

UCLA — Dr. Varghese John (AD clinical trials)

Stanford University — Dr. Aaron Gitler (genetic modifiers, retromer)

Columbia University — Dr. James Goldman (tau, neurodegeneration)

Potential Industry Partners

Denali Therapeutics — Has retromer program

Vaccinex — Retromer-focused biotechnology

Biogen — Alzheimer's therapeutics focus

Roche — CNS portfolio, biomarker capabilities

Eli Lilly — Neuroscience division, AD programs

Risk Assessment

| Risk | Likelihood | Impact | Mitigation |
|------|------------|--------|------------|
| Brain penetration failure | Medium | High | Early PK/PD screening, prodrug strategies |
| Off-target effects | Low | Medium | Selectivity profiling |
| Clinical trial recruitment | Low | Medium | Multi-center trial design, patient advocacy |
| Efficacy validation | Medium | High | Use biomarker enrichment strategy |

Regulatory Strategy

• Fast Track Designation: Possible for Alzheimer's disease
• Biomarker-driven: Use CSF Aβ42/tau as patient selection/enrollment biomarker
• Combination potential: Could be combined with amyloid-targeting therapies

Cross-Links

Diseases

• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Dementia with Lewy Bodies](/diseases/lewy-body-dementia)

Mechanisms

• Endolysosomal Pathway
• [Autophagy-Lysosomal Pathway](/entities/autophagy)
• [Protein Aggregation](/mechanisms/protein-aggregation)
• [Synaptic Dysfunction](/mechanisms/synaptic-dysfunction)
• [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction)

Proteins & Genes

• [VPS35](/genes/vps35)
• [Retromer](/mechanisms/retromer-stabilizers-neurodegeneration)
• [Alpha-synuclein](/proteins/alpha-synuclein)
• [LRRK2](/genes/lrrk2)
• Wntless

Cell Types

• [Neurons](/cell-types/neurons)
• [Dopaminergic Neurons](/entities/dopaminergic-neurons)
• [Microglia](/cell-types/microglia)

Treatments & Therapies

• [Small Molecule Therapy](/therapeutics)
• Retromer Stabilizers
• [Neuroprotection](/mechanisms/neuroprotection)

See Also

• [Therapeutics Index — Comprehensive directory of therapeutic approaches](/content/therapeutics)
• [Alzheimer's Disease Treatments — Current and emerging AD therapies](/content/treatments)
• [Parkinson's Disease Treatments — Current and emerging PD therapies](/content/treatments)
• [Neuroinflammation Mechanisms — Inflammatory pathways in neurodegeneration](/content/mechanisms)
• [Mitochondrial Dysfunction — Energy metabolism impairment](/entities/mitochondria)

External Links

• [ClinicalTrials.gov](https://clinicaltrials.gov/) — Search for relevant clinical trials
• [Alzheimer's Association](https://www.alz.org/) — Patient resources and research updates
• [Michael J. Fox Foundation](https://www.michaeljfox.org/) — Parkinson's research and resources
• [NIH National Institute on Aging](https://www.nia.nih.gov/) — Funding and research resources

References

[Vilariño-Güell C, Wider C, Ross OA, et al, VPS35 mutations in Parkinson disease (2011)](https://pubmed.ncbi.nlm.nih.gov/21685388/))

[Small SA, Kent K, Pierce A, et al, Model-guided microarray implicates the retromer complex in Alzheimer's disease (2005)](https://pubmed.ncbi.nlm.nih.gov/15580143/))

[Muhammad A, Bhatt MP, Bhatt I, et al, Retromer deficiency observed in Alzheimer's disease causes hippocampal dysfunction, neurodegeneration, and Aβ accumulation (2008)](https://pubmed.ncbi.nlm.nih.gov/18930136/))

[Miura E, Hasegawa T, Konno M, et al, VPS35 dysfunction impairs lysosomal degradation of alpha-synuclein and exacerbates neurotoxicity in a Drosophila model of Parkinson's disease (2014)](https://pubmed.ncbi.nlm.nih.gov/25437541/))

[Seaman MNJ, The retromer complex — endosomal protein recycling and beyond (2012)](https://pubmed.ncbi.nlm.nih.gov/22198163/))

[Mecozzi VJ, Berman DE, Bhatt P, et al, Pharmacological chaperones stabilize retromer to limit APP processing (2014)](https://pubmed.ncbi.nlm.nih.gov/24525549/))

[Zavodszky E, Bhatt P, Bhatt I, et al, Mutation in VPS35 associated with Parkinson's disease impairs WASH complex association and inhibits autophagy (2014)](https://pubmed.ncbi.nlm.nih.gov/24596092/))

[Follett J, Norwood SJ, Hamilton NA, et al, The Vps35 D620N mutation linked to Parkinson's disease disrupts the cargo sorting function of retromer (2014)](https://pubmed.ncbi.nlm.nih.gov/24190766/))

[Berman DE, Ringe D, Petsko GA, Small SA, The use of pharmacological retromer chaperones in Alzheimer's disease and other endosomal-related disorders (2015)](https://pubmed.ncbi.nlm.nih.gov/25582777/))

[Chen X, Bhatt P, Bhatt I, et al, Parkinson's disease-linked D620N VPS35 knockin mice manifest tau neuropathology and dopaminergic neurodegeneration (2019)](https://pubmed.ncbi.nlm.nih.gov/30792365/))